CONTEXT: Evidence regarding the accuracy of [(123)I] metaiodobenzylguanidine (MIBG) imaging for phaeochromocytoma localization is currently limited to small series. OBJECTIVE: We present the largest series of primary phaeochromocytomas in which the performance of [(123)I]MIBG has been evaluated and correlated with cross-sectional imaging. DESIGN: We identified 76 patients with both preoperative [(123)I]MIBG and cross-sectional imaging for confirmed primary phaeochromocytoma between 1995 and 2005 at our institution. This comprised 60 adrenal tumours in 55 patients and 33 extra-adrenal tumours in 23 patients (2 patients had both adrenal and extra-adrenal tumours). Phaeochromocytoma metastases were not evaluated. MAIN OUTCOME MEASURE(S): [(123)I]MIBG studies were independently reviewed and correlated with CT and MRI examinations, as well as tumour functional status, to identify features that may predict a false negative [(123)I]MIBG result. RESULTS: The overall sensitivity of [(123)I]MIBG was 75%. Tumour detection was lower for extra-adrenal (58%) vs. adrenal (85%) phaeochromocytomas (P = 0.005). For extra-adrenal tumours, [(123)I]MIBG demonstrated 8 of 14 carotid body, 2 of 2 intrathoracic, 8 of 14 retroperitoneal and 2 of 3 pelvic phaeochromocytomas. Overall, MRI and CT demonstrated 68 of 68 and 72 of 74 primary phaeochromocytomas, respectively. Tumour size correlated with [(123)I]MIBG uptake for adrenal (P = 0.009) but not extra-adrenal tumours. When tumours were adjusted for size, no other imaging feature or functional status correlated with [(123)I]MIBG negativity, although two large [(123)I]MIBG negative adrenal tumours contained large areas of necrosis or haemorrhage. CONCLUSIONS: Extra-adrenal and small adrenal phaeochromocytomas are more likely to result in false negatives on [(123)I]MIBG. Tumoural necrosis or haemorrhage do not consistently relate to [(123)I]MIBG uptake, although adrenal phaeochromocytomas containing minimal solid tissue due to extensive necrosis may predict a negative [(123)I]MIBG result.
CONTEXT: Evidence regarding the accuracy of [(123)I] metaiodobenzylguanidine (MIBG) imaging for phaeochromocytoma localization is currently limited to small series. OBJECTIVE: We present the largest series of primary phaeochromocytomas in which the performance of [(123)I]MIBG has been evaluated and correlated with cross-sectional imaging. DESIGN: We identified 76 patients with both preoperative [(123)I]MIBG and cross-sectional imaging for confirmed primary phaeochromocytoma between 1995 and 2005 at our institution. This comprised 60 adrenal tumours in 55 patients and 33 extra-adrenal tumours in 23 patients (2 patients had both adrenal and extra-adrenal tumours). Phaeochromocytoma metastases were not evaluated. MAIN OUTCOME MEASURE(S): [(123)I]MIBG studies were independently reviewed and correlated with CT and MRI examinations, as well as tumour functional status, to identify features that may predict a false negative [(123)I]MIBG result. RESULTS: The overall sensitivity of [(123)I]MIBG was 75%. Tumour detection was lower for extra-adrenal (58%) vs. adrenal (85%) phaeochromocytomas (P = 0.005). For extra-adrenal tumours, [(123)I]MIBG demonstrated 8 of 14 carotid body, 2 of 2 intrathoracic, 8 of 14 retroperitoneal and 2 of 3 pelvic phaeochromocytomas. Overall, MRI and CT demonstrated 68 of 68 and 72 of 74 primary phaeochromocytomas, respectively. Tumour size correlated with [(123)I]MIBG uptake for adrenal (P = 0.009) but not extra-adrenal tumours. When tumours were adjusted for size, no other imaging feature or functional status correlated with [(123)I]MIBG negativity, although two large [(123)I]MIBG negative adrenal tumours contained large areas of necrosis or haemorrhage. CONCLUSIONS: Extra-adrenal and small adrenal phaeochromocytomas are more likely to result in false negatives on [(123)I]MIBG. Tumoural necrosis or haemorrhage do not consistently relate to [(123)I]MIBG uptake, although adrenal phaeochromocytomas containing minimal solid tissue due to extensive necrosis may predict a negative [(123)I]MIBG result.
Authors: Jay S Fonte; Jeremyjones F Robles; Clara C Chen; James Reynolds; Millie Whatley; Alexander Ling; Leilani B Mercado-Asis; Karen T Adams; Victoria Martucci; Tito Fojo; Karel Pacak Journal: Endocr Relat Cancer Date: 2012-02-13 Impact factor: 5.678
Authors: Juan P Brito; Noor Asi; Michael R Gionfriddo; Catalina Norman; Aaron L Leppin; Claudia Zeballos-Palacios; Chaitanya Undavalli; Zhen Wang; Juan P Domecq; Gabriela Prustsky; Tarig A Elraiyah; Larry J Prokop; Victor M Montori; Mohammad Hassan Murad Journal: Endocrine Date: 2015-02-06 Impact factor: 3.633
Authors: Kathryn S King; Clara C Chen; Dimitrios K Alexopoulos; Millie A Whatley; James C Reynolds; Nicholas Patronas; Alexander Ling; Karen T Adams; Paraskevi Xekouki; Howard Lando; Constantine A Stratakis; Karel Pacak Journal: J Clin Endocrinol Metab Date: 2011-07-13 Impact factor: 5.958
Authors: Giuliano Mariani; Laura Bruselli; Torsten Kuwert; Edmund E Kim; Albert Flotats; Ora Israel; Maurizio Dondi; Naoyuki Watanabe Journal: Eur J Nucl Med Mol Imaging Date: 2010-02-25 Impact factor: 9.236
Authors: Henri J L M Timmers; Clara C Chen; Jorge A Carrasquillo; Millie Whatley; Alexander Ling; Bastiaan Havekes; Graeme Eisenhofer; Lucia Martiniova; Karen T Adams; Karel Pacak Journal: J Clin Endocrinol Metab Date: 2009-10-28 Impact factor: 5.958